Form 4: Beta Bionics Officer Sells Shares Under 10b5-1 Plan

Beta Bionics Chief Commercial Officer Mark Hopman sold 1,258 shares of common stock for approximately $18,875 under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Mark Hopman, Chief Commercial Officer of Beta Bionics, Inc., reported a transaction on June 24, 2026.
• He sold 1,258 shares of common stock.
• The sale was executed under a Rule 10b5-1 trading plan adopted on May 13, 2025.
• The weighted average sale price was $15.0083, with prices ranging from $15.00 to $15.015.
• Following the sale, Hopman beneficially owns 129,354 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the transaction is a routine stock sale by an executive under a pre-established 10b5-1 plan, which is a standard practice and not indicative of negative company performance.

Negatives

• Insider selling can sometimes be perceived negatively by the market, although this sale was conducted under a pre-established plan.

Future Outlook

No specific future outlook or guidance is provided in this filing, as it pertains to a stock transaction by an insider.

Industry Context

StockSavvy.ai notes that insider sales under Rule 10b5-1 plans are common and are designed to provide an affirmative defense against allegations of insider trading by allowing executives to sell shares at predetermined times and prices. This filing indicates routine portfolio management by an executive.

Stakeholder Impact

• Shareholders: The sale of shares by an executive may be monitored, but the pre-arranged nature of the 10b5-1 plan mitigates concerns about insider trading. The impact on share price is likely minimal given the volume and plan structure.

Key Dates

Keywords

Form 4, Insider Trading, Rule 10b5-1, Beta Bionics, BBNX, Stock Sale, Executive Transactions